Thursday 16 October, 2025
Physiologically-based pharmacokinetic (PBPK) modeling of the combination of ivacaftor and lefamulin in Cystic Fibrosis patients Wolfgang W. Wicha1, Magali…
Read moreAbstracts
Physiologically based pharmacokinetic modelling to predict the concentration-time profile of an antibody-drug conjugate and hepatic and renal impairment.
Thursday 16 October, 2025
Introduction: Antibody-drug conjugates (ADC) present a promising treatment option in oncology. Antibodies have high specificity for their cognate antigens and…
Read moreModelling antibody levels impact on infection and SARS-CoV2 replication
Thursday 16 October, 2025
Introduction: Despite unprecedented efforts to tackle a pandemic, SARS-CoV-2 is still circulating at a high rate and will most likely…
Read moreIndividualized dosing regimen optimization of ustekinumab through a population pharmacokinetic-pharmacodynamic model in patients with psoriasis
Thursday 16 October, 2025
Introduction: Psoriasis (Pso) is an inflammatory skin disease triggered by genetic, environmental, and immunological factors (1,2). Monoclonal antibodies represent a…
Read morePharmacometric modeling to capture the time varying pharmacokinetics of PEG-asparaginase in acute lymphoblastic leukemia: A multi-protocol analysis from Nordic and Baltic countries
Thursday 16 October, 2025
Introduction: Acute lymphoblastic leukemia (ALL) is the most prevalent form of pediatric cancer, accounting for approximately 6540 new cases and over…
Read moreEvaluation of automated model development workflows for population pharmacokinetic models
Thursday 16 October, 2025
Introduction: Automated model development workflows to identify the optimal population pharmacokinetic (PK) model – as implemented in Pharmpy open-source software…
Read morePopulation pharmacokinetic model of encorafenib and binimetinb in real life settings
Thursday 16 October, 2025
Objectives: The RAS/RAF/MEK/ERK signaling pathway plays a pivotal role in the pathogenesis of numerous cancers, leading to the development of…
Read moreODE-free survival modeling with full pharmacokinetic profiles in the IMPRES-M framework
Thursday 16 October, 2025
Introduction: Time to event analysis (TTE) characterizes the probability that an event, such as a disease progression, occurs, and in…
Read moreArtificial Intelligence and Machine Learning for Next-Generation Model-Informed Precision Medicine: A Tutorial on Practical Applications and Pitfalls
Thursday 16 October, 2025
This tutorial will cover the integration of advanced data analytics, specifically Artificial Intelligence (AI) and Machine Learning (ML), into model-informed…
Read moreDevelopment of a novel open-source Physiology-Based Biopharmaceutics Modelling (PBBM) framework using the Open System Pharmacology suite
Thursday 16 October, 2025
Replacing animal testing by in silico and in vitro methods is crucial for ethical and sustainable drug development. Physiology Based…
Read more